We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma (APROMISS)

This study is currently recruiting participants.
Verified September 2017 by Advenchen Laboratories, LLC
Sponsor:
ClinicalTrials.gov Identifier:
NCT03016819
First Posted: January 11, 2017
Last Update Posted: September 28, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Advenchen Laboratories, LLC
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: August 2021
  Estimated Primary Completion Date: April 2021 (Final data collection date for primary outcome measure)